Maintenance chemotherapy of acute lymphoblastic leukemia in children. Clinical and pharmacological aspects of the monitoring and adjustment of oral methotrexate and 6-mercaptopurine dosage

Danish Medical Bulletin

Volumn 45, Issue 5, 1998, Pages 510-532

  Schmiegelow, Kjeld ^a  

^a University of Copenhagen

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MERCAPTOPURINE; METHOTREXATE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; DRUG INDUCED DISEASE; DRUG MONITORING; HUMAN; LEUKOPENIA; LIVER TOXICITY; ORAL DRUG ADMINISTRATION; REVIEW; THROMBOCYTOPENIA;

6-MERCAPTOPURINE; ADMINISTRATION, ORAL; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; METHOTREXATE;

EID: 0031762961     PISSN: 09078916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (291)

1. Anonymous (1971). Treatment of acute lymphoblastic leukaemia. Comparison of immunotherapy (B.C.G.), intermittent methotrexate, and no therapy after a five-month intensive cytotoxic regimen ((Concord trial). Preliminary report to the Medical Research Council by the Leukaemia Committee and the Working Party on Leukaemia in Childhood. Br Med J 4: 189-194.
2. Anonymous (1988), Treatment of childhood acute lymphoblastic leukemia. Lancet ii: 683-685.
3. Aarbakke J (1995). Biology and pharmacology of thiopurines. Pediatr Hematol Oncol 12: 511-519.
4. Agarwal RP, Scholar EM, Agarwal KC, Parks RE (1971). Identification and isolation on a large scale of guanylate kinase from human erythrocytes. Effects of monophosphate nucleotides of purine analogs. Biochem Pharmacol 20: 1341-1354.
5. Aherne GW, Quinton M (1981). Techniques for the measurement of methotrexate in biological samples. Cancer Treat Rep 65 Suppl 1: 55-60.
6. Arico M, Maggiore G, Silini E, Bono F, Vigano F, Cerino A, Mondelli MU (1994). Hepatitis C virus infection in children treated for acute lymphoblastic leukemia. Blood 84: 2919-2922.
7. Aur RJA, Simone JV, Verzosa MS, et al. (1978). Childhood acute lymphocytic leukemia Study VIII. Cancer 42: 2123-2134.
8. Balis FM, Savitch JL, Bleyer WA (1983). Pharmacokinetics of oral methotrexate in children. Cancer Res 43: 2342-2345.
9. Balis FM, Holcenberg JS, Zimm S, et al. (1987). The effect of methotrexate on the bioavilability of oral 6-mercaptopurine. Clin Pharmacol Ther 41: 384-387.
10. Balis FM, Jeffries SL, Lange B, et al. (1989). Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy?. Am J Pediatr Hematol Oncol 11: 324-326.
11. Barredo JC, Synold TW, Laver J, Relling MV, Pui CH, Priest DG, Evans WE (1994). Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 84: 564-569.
12. Baugh CM, Krumdieck CL, Nair MG (1973). Polygammaglutamyl metabolites of methotrexate. Biochem Biophys Res Commun 52: 27-34.
13. Baumer JH, Mott MG (1978). Sex and prognosis in childhood acute lymphoblastic leukemia. Lancet ii: 128-129.
14. Bennett LL, Jr., Allan PW (1971). Formation and significance of 6-methylthiopurine ribonucleotide as a metabolite of 6-mercaptopurine. Cancer Res 31: 152-158.
15. Berkovitch M, Matsui D, Zipursky A, et al. (1996). Hepatotoxicity of 6-mercaptopurine in childhood acute lymphoblastic leukemia: pharmacokinetic characteristics. Med Ped Oncol 26: 85-89.
16. Blatt J (1995). Studying survivors of childhood cancer for late effects of therapy. Int J Ped Hematol Oncol 2: 325-336.
17. Bleyer WA (1977). Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 61: 1419-1425.
18. Bleyer WA (1978). The clinical pharmacology of methotrexate. Cancer 41: 36-51.
19. Borsi JD (1988). New aspects of the clinical pharmacokinetics of methotrexate. The University of Trondheim (Thesis).
20. Borsi JD, Moe PJ (1987). Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children, Cancer 60: 3020-3024.
21. Bostrom B, Erdmann G (1993). Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 15: 80-86.
22. Bostrom B, Erdmann G (1992). Association of relapse with mercaptopurine (6MP) cellular pharmacokinetics (CPK) in children with acute lymphoblastic leukemia (ALL). Proc Am Soc Clin Oncol 11: 278 (Abstract).
23. Bökkerink JPM, Bakker MAH, Hulscher TW, DeAbreu RA, Schretlen EDAM (1988). Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages. Biochem Pharmacol 37: 2321-2327.
24. Bökkerink JPM, Damen FJ, Hulscher MW, Bakker MA, De Abreu RA (1990). Biochemical evidence for synergistic combination treatment with methotrexate and 6-mercaptopurine in acute lymphoblastic leukemia. Hamatol Bluttransfus 33: 110-117.
25. Brisco MJ, Condon J, Hughes E, et al. (1994). Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 343: 196-200.
26. Brunschede H, Krooth RS (1973). Studies on the xanthine oxidase activity in mammalian cells. Biochem Genet 8: 341-350.
27. Bruunshuus I, Schmiegelow K (1989). Analysis of 6-mercaptopurine, 6-thioguanine nucleotides, and 6-thiouric acid in biological fluids by high-performance liquid chromatography. Scand J Clin Lab Invest 49: 779-784.
28. Burchenal JH, Murphy ML, Ellison RR, et al. (1953). Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood 8: 965-987.
29. Burton NK, Barnett MJ, Aherne GW, Evans J, Douglas I, Lister T (1986). The effect of food on the oral administration of 6-mercaptopurine. Cancer Chemother Pharmacol 18: 90-91.
30. Camitta BM, Leventhal B, Lauer S, et al. (1989). Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol 7: 1539-1544.
31. Campana D, Kumagai M, Manabe A, et al. (1993). Hyperploid acute lymphoblastic leukemia (ALL): a distinct biologic entity with marked propensity to programmed cell death. Blood 82 (suppl. 1): 49a (Abstract).
32. Cannistra SA, Griffin JD (1988). Regulation of the production and function og granulocytes and monocytes. Semin Hematol 25: 173-188.
33. Carde P, MacKintosh FR, Rosenberg SA (1983). A dose and time response analysis in the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1: 146-153.
34. Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Kouzumi S (1985). Polyglutamation of methotrexate: is methotrexate a prodrug? J Clin Invest 76: 907-912.
35. Chabner BA (1988). In celebration of a Nobel Prize (editorial). J Natl Cancer Inst 80: 1512-1513.
36. Chandler MHH, Blouin RA (1992). Dietary influences on drug disposition. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied Pharmacokinetics: Principles of therapeutic drug monitoring. 3rd edn. Applied Therapeutics, Inc. Vancouver: 12.1-12.17.
37. Chessells JM, Hardisty RM, Rapson NT (1977). Acute lymphoblastic leukaemia in children: Classification and prognosis. Lancet ii: 1307-1309.
38. Chessells JM, Hardisty RM, Richards S (1987a). Long survival in childhood lymphoblastic leukaemia. Br J Cancer 55: 315-319.
39. Chessells JM, Leiper AD, Tiedemann K, Hardisty RM, Richards S (1987b). Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukaemia. Arch Dis Child 62: 172-176.
40. Chessells JM, Cox TC, Kendall B, Cavanagh NP, Jannoun L, Richards S (1990). Neurotoxicity in lymphoblastic leukaemia: comparison of oral and intramuscular methotrexate and two doses of radiation. Arch Dis Child 65: 416-422.
41. Chessells JM (1992). Treatment of childhood acute lymphoblastic leukaemia: present issues and future prospects. Blood Rev 6: 193-203.
42. Cheung NK, Heller G (1991). Chemotherapy dose intensity correlates strongly with response, median survival, and median, progression-free survival in metastatic neuroblastoma. J Clin Oncol 9: 1050-1058.
43. Childhood ALL Collaborative Group (1996). Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukemia: overview of 42 trials involving 12000 randomised children. Lancet 347: 1783-1788.
44. Christie NT, Drake S, Meyn RE, Nelson JA (1984). 6-Thioguanine-induced DNA damage as a determinant of cytotoxicity in cultured Chinese hamster ovary cells. Cancer Res 44: 3665-3671.
45. Clausen N, Scheibel E, Nyboe J (1984). Prognostic factors for relapsefree survival in childhood acute lymphoblastic leukemia. Scand J Haematol 33: 295-300.
46. Conn J, Jordal R (1982). Reference values for hematological investigations. Scand J Soc Med Suppl.30: 11-17.
47. Cortes EP, Holland JF, Glidewell O (1979). Adjuvant treatment of primary osteosarcoma: Cancer and Leukemia Group B experience. Recent Results Cancer Res 68: 16-24.
48. Cousens P, Waters B, Said J, Stevens M (1988). Cognitive effects of cranial irradiation in leukaemia: a survey and meta-analysis. J Child Psychol Psychiatry 29: 839-852.
49. Cox DR (1972). Regression models and life-tables (with discussion). J R Stat Soc (B) 34: 187-220.
50. Craft AW, Kay H, Lawson DN, McElwain TJ (1977). Methotrexate-induced malabsorption in children with acute lymphoblastic leukaemia. Br Med J 2: 1511-1512.
51. Craft AW, Rankin A, Aherne W (1981). Methotrexate absorption in children with acute lymphocytic leukemia. Cancer Treat Rep 65 (suppl 1): 77-81.
52. da Costa M, Iqbal MP (1981). The transport and accumulation of methotrexate in human erythrocytes. Cancer 48: 2427-2432.
53. Davidson GP, Townley RRW (1977). Structural and functional abnormalities of the small intestine due to nutritional folic acid deficiency in infancy. J Pediatr 90: 590.
54. Davies HA, Lennard L, Lilleyman JS (1993). Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance? BMJ 306: 1239-1240.
55. Dibenedetto SP, Guardabasso V, Ragusa R, Di Cataldo A, Miraglia V, D'Amico S, Ippolito AM (1994). 6-Mercaptopurine cumulative dose: A critical factor of maintenance therapy in average risk childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 11: 253-258.
56. Dolan G, Lilleyman JS, Richards SM (1989). Prognostic importance of myelosuppression during maintenance treatment of lymphoblastic leukaemia. Leukaemia in Childhood Working Party of the Medical Research Council. Arch Dis Child 64: 1231-1234.
57. Eden OB, Lilleyman J, Shaw MP, Richards S, Peto J (1987). Medical Research Council Childhood Leukaemia Trial VIII compared with trials II-VII: lessons for future management. Hamatol Bluttransfus 30: 448-455.
58. Einhorn M, Davidson I (1964). Hepatotoxicity of mercaptopurine. JAMA 188: 802-806.
59. Elion GB (1967). Symposium on immunosuppressive drugs. Biochemistry and pharmacology of purine analogues. Fed Proc 26: 898-904.
60. EORTC Pharmacokinetic and Metabolism Group (1987). Pharmacologically guided dose escalation in phase I trial. Commentary and proposed guidelines. Eur J Cancer Clin Oncol 23: 1083-1087.
61. Ernst P, Killman S (1971). Pertuberation of generation cycle of human leukemic myeloblasts in vivo by methotrexate. Blood 38: 689-705.
62. Evans WE, Crom WR, Sinkule JA, et al. (1983). Pharmacokinetics of anticancer drugs in children. Drug Metab Rev 14: 847-886.
63. Evans WE, Crom WR, Stewart CF, et al. (1984). Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukemia. Lancet 1: 359-362.
64. Evans WE, Crom WR, Abromowitch M, et al. (1986). Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia - identification of a relation between concentration and effect. N Eng J Med 314: 471-477.
65. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM (1991a). Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 119: 985-989.
66. Evans WE, Rodman J, Relling MV, Crom WR, Rivera GK, Crist WM, Pui CM (1991b). Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. Semin Hematol 28: 15-21.
67. Evans WE, Rodman JH, Relling MV, Crom WR, Rivera GK, Pratt CB, Crist WM (1991c). Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugs. Med Pediatr Oncol 19: 153-159.
68. Fabre I, Fabre G, Goldman ID (1984). Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res 44: 3190-3195.
69. Fairchild CR, Maybaum J, Kennedy KA (1986). Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment. Biochem Pharmacol 35: 3533-3541.
70. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA (1948). Temporary remissions in acute leukemia in children produced by folic acid antagonist 4-aminopteroylglutamic acid (aminopterin). N Engl J Med 238: 787-793.
71. Fields T, Brox L (1974). Purine and pyrimidine pool sizes and purine utilization in human lymphocytes and cultured lymphoblasts. Can J Biochem 52: 441-446.
72. Frei E 3rd., Freireich EJ, Gehan E, et al. (1961). Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate. Blood 18: 431-454.
73. Frei E 3rd., Caron M, Levin RH, et al. (1965). The effectiveness of combinations of antileukemia agents in inducing and maintaining remission in children with acute leukemia. Blood 26: 642-656.
74. Frei E 3rd., Canellos G (1980). Dose: A critical factor in cancer chemotherapy. Am J Med 69: 585-594.
75. Freireich EJ, Gehan E, Frei E 3rd., et al. (1963). The effect of 6-mercaptopurine on the duration of steroid-induced remission in acute leukemia: a model for evaluation of other potentially useful therapy. Blood 21: 699-716.
76. Galpin AJ, Evans WE (1993). Therapeutic drug monitoring in cancer management. Clin Chem 39: 2419-2430.
77. Gaynon P, Bleyer WA, Steinherz P, et al. (1987). Impact of treatment dose and delay on the disease free survival (DFS) of children with acute lymphoblastic leukemia (ALL) and unfavourable prognostic features. Proc Am Soc Clin Oncol 6: 156.
78. Gaynon P, Bleyer WA, Steinherz PG, et al. (1990). Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavourable presenting features. Med Ped Oncol 18: 273-279.
79. Gaynon P, Steinherz P, Bleyer WA, et al. (1991). Association of delivered drug dosage and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 19: 221-227.
80. Gobrecht O, Gobel U, Graubner U, Gutjahr P, Schock V, Spaar HJ, Janka Schaub GE (1992). Effect of dose intensity and therapy-induced leukocytopenia in intensive therapy on the prognosis of acute lymphatic leukemia in childhood. Results in 213 patients of the COALL-85 study. Klin Padiatr 204: 230-235.
81. Graham ML, Shuster JJ, Kamen BA, et al. (1992). Red blood cell methotrexate and folate levels in children with acute lymphoblastic leukemia undergoing therapy: a Pediatric Oncology Group pilot study. Cancer Chemother Pharmacol 31: 217-222.
82. Greaves M, Janossy G, Peto J, et al. (1981). Immunologically defined subclasses of acute lymphoblastic leukemia in children: their relationship to presentation features and prognosis. Br J Haematol 48: 179-197.
83. Guerciolini R, Szumlanski C, Weinshilboum RM (1991). Human liver xanthine oxidase: nature and extent of individual variation. Clin Pharmacol Ther 50: 663-672.
84. Gustafsson G, Berglund G, Garwicz S, et al. (1989). A population-based study of children with standard risk acute lymphoblastic leukemia in the five Nordic countries. Acta Paediatr Scand 78: 104-109.
85. Hale JP, Lilleyman JS (1991). Importance of 6-mercaptopurine dose in lymphoblastic leukemia. Arch Dis Child 66: 462-466.
86. Hamilton L, Elion GB (1954). The fate of 6-mercaptopurine in man. Ann N Y Acad Sci 60: 304-314.
87. Hammond D, Sather H, Nesbit M, et al. (1986). Analysis of prognostic factors in acute lymphoblastic leukemia. Med Ped Oncol 14: 124-134.
88. Hande KR (1991). Drug monitoring in cancer therapy. J Natl Cancer Inst 83: 1523-1524.
89. Harb JM, Werlin SL, Camitta BM, Oechler H, Kamen BA, Blank EL (1983). Hepatic ultrastruclure in leukemic children treated with methotrexate and 6-mercaptopurine. Am J Pediatr Hematol Oncol 5: 323-331.
90. Harter JG, Peck CC (1991). Chronobiology. Suggestions for integrating it into drug development. Ann N Y Acad Sci 618: 563-571.
91. Harvey VJ, Slevin ML, Woollard RC, Johnston A, Barnett MJ, Wrigley PF, Turner P (1984). The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle. Cancer Chemother Pharmacol 13: 91-94.
92. Hayder S, Lafolie P, Björk O, Peterson C (1989). 6-mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity. Ther Drug Monit 11: 617-622.
93. Hayder S, Björk O, Lafolie P (1990). The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia. Acta Paediatr Scand 79: 832-837.
94. Hayder S, Björk O, Nilsson B (1992). Relapse factors during maintenance therapy of acute lymphoblastic leukemia in children. Pediatr Hematol Oncol 9: 21-27.
95. Hendel J (1985). Clinical pharmacokinetics of methotrexate in psoriasis therapy. Dan Med Bull 32: 329-337.
96. Hendel J, Poulsen H, Nyfors B, Nyfors A (1985). Changes in liver histology during methotrexate therapy of psoriasis correlated to the concentration of methotrexate and folate in erythrocytes. Acta Pharmacol Toxicol Copenh 56: 321-326.
97. Hendel J, Nyfors A (1984a). Pharmacokinetics of methotrexate in erythrocytes in psoriasis. Eur J Clin Pharmacol 27: 607-610.
98. Hendel J, Nyfors A (1984b). Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption. Eur J Clin Pharmacol 26: 121-124.
99. Hendel J, Nyfors A (1988). Single-point MTX erythrocyte levels in relation to progressive liver fibrosis. Acta Derm Venereol Stockh 68: 91.
100. Herber S, Lennard L, Lilleyman JS, Maddocks JL (1982). 6-mercaptopurine: Apparent lack of relation between prescribed dose and biological effect in children with leukaemia. Br J Cancer 46: 138-141.
101. Higuchi T, Nakamura T, Wakisaka G (1976). Metabolism of 6-mercaptopurine in human leukemic cells. Cancer Res 36: 3779-3783.
102. Higuchi T, Nakamura T, Uchino H, Wasikaka G (1977). Comparative study of 6-mercaptopurine metabolism in human leukemic leukocytes and L1210 cells. Antimicr Agents Chemother 12: 518-522.
103. Hill DL, Bennett LL (1980). Purification and properties of 5-phosphoribosyl pyrophosphate amidotransferase from adenocarcinoma 755 cells. Biochemistry 8: 122-130.
104. Holmes EW, McDonald JA, McCord JM, Wyngaarden JB, Kelley WN (1973). Human glutamine phosphoribosylpyrophosphate amidotransferase. Kinetic and regulatory properties. J Biol Chem 248: 144-150.
105. Hrushesky WJM, Bjarnason GA (1993). Circadian cancer therapy. J Clin Oncol 11: 1403-1417.
106. Hryniuk W, Bush H (1984). The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281-1288.
107. Hryniuk WM (1988). The importance of dose intensity in the outcome of chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology. J.B.Lippincott, Philadelphia: 121-141.
108. Hryniuk WM (1990). Integrating the concept of dose intensity into a strategy for systemic therapy of malignant disease. Prog Clin Biol Res 354B: 93-101.
109. Jacobs SA, Adamson RH, Chabner BA, Derr CJ, Johns DG (1975). Stoichiometric inhibition of mammalian dihydrofolate reductase by the gamma-glutamyl metabolite of methotrexate 4-amino-4-deoxy-N10-methylpteroylglutamyl-gamma-glutamate. Biochem Biophys Res Commun 63: 9692-698.
110. Janka Schaub GE, Stuhrk H, Kortum B, et al. (1991). Initial response to therapy as an important prognostic factor in acute lymphoblastic leukemia in childhood. COALL study group, Klin Padiatr 203: 231-235.
111. Johnston HP, Hawley P, White SE, Gibson I, Tidd DM (1985). The effects of 6-mercaptopurine nucleotide derivatives on the growth and survival of 6-mercaplopurine-sensitive and -resistant cell culture lines. Br J Cancer 51: 505-514.
112. Jolivet J, Cowan KH, Curt GA, et al. (1983). The pharmacology and clinical use of methotrexate. N Eng J Med 309: 1094-1104.
113. Kamen BA, Takach PL, Vatev R, Caston JD (1976). A rapid, radiochemical-ligand binding assay for methotrexate. Anal Biochem 70: 54-63.
114. Kamen BA, Nylen PA, Camitta BM, Bertino JR (1981). Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug. Br J Haematol 49: 355-360.
115. Kamen BA, Holcenberg JS, Turo K, Whitehead VM (1984). Methotrexate and folate content of erythrocytes in patients receiving oral vs intramuscular therapy with methotrexate. J Pediatr 104: 131-133.
116. Kane MA, Portillo RM, Elwood PC, Antony AC, Kolhouse JF (1961). The influence of extracellular folate concentration on the methotrexate uptake by human KB cells. J Biol Chem 261: 44-49.
117. Kaplan EL, Meier P (1958). Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481.
118. Kato Y, Matsushita T, Chiba K, Hijiya N, Yokoyama T, Ishizaki T (1991). Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia. J Pediatr 119: 311-316.
119. Kearney PJ, Light PA, Preece A, Mort MG (1979). Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 3: 117-120.
120. Kelley WN, Rosenbloom FM, Seegmiller JE (1967). Effects of azathioprine on purine synthesis in clinical disorders of purine metabolism. J Clin Invest 46: 1518-1529.
121. Kisliuk RL, Gaumont Y, Baugh CM, Galivan JH, Maley GF, Maley F (1979). Inhibition of thymidylate synthetase by poly-gamma-glutamyl derivates of folate and methotrexate. In: Kisliuk RL, Brown (eds) Chemistry and biology of pteridines. Elsevier North Holland, Amsterdam: 431-435.
122. Knoester PD, Underberg WJ, Beijnen JH (1993). Clinical pharmacokinetics and pharmacodynamics of anticancer agents in pediatric patients (review). Anticancer Res 13: 1795-1808.
123. Kobayashi K, Jodrell DI, Ratain MJ (1993). Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring. Cancer Surv 17: 51-78.
124. Kong CM, Parks RE (1975). Incorporation of the purine moieties of guanosine and inosine analogs into nucleotide pools of erythrocytes. Biochem Pharmacol 24: 807-813.
125. Konishi Y, Ichihara A (1979). Transfer of purines from liver to erythrocytes. In vivo and in vitro studies. J Biochem Tokyo 85: 295-301.
126. Koren G, Solh H, Klein J, Soldin SJ, Greenberg M (1989). Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics. Med Pediatr Oncol 17: 450-454.
127. Koren G, Ferrazini G, Sulh H, et al. (1990a). Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Engl J Med 323: 17-21.
128. Koren G, Langevin AM, Olivieri N, Giesbrecht E, Zipursky A, Greenberg M (1990b). Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. Am J Dis Child 144: 1135-1137.
129. Koren G, Ferrazzini G, Sohl H, Robieux I, Johnson D, Giesbrecht E (1992). Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. Chronobiol Int 9: 434-438.
130. Krakower GR, Kamen BA (1983). Methotrexate metabolism. Cancer Chemother Pharmacol 10: 230-231.
131. Krakower GR, Kamen BA (1984). The reticulocytic rat: a model for analysis of methotrexate polyglutamate dynamics in situ. J Pharmacol Exp Ther 231: 43-47.
132. Lafolie P, Hayder S, Björk O, Åhström L, Liliemark J, Peterson C (1986). Large interindividual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukaemia and non-Hodgkin lymphoma. Acta Paediatr Scand 75: 797-803.
133. Lafolie P, Björk O, Hayder S, Ahstrom L, Peterson C (1989). Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia. Med Oncol Tumor Pharmacother 6: 259-265.
134. Lafolie P, Hayder S, Björk O, Peterson C (1991). Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia. Eur J Clin Pharmacol 40: 599-601.
135. Langevin A, Koren G, Soldin SJ, Greenberg M (1987). Pharmacokinetic case for giving 6-mercaptopurine maintenance doses at night. Lancet 2: 505-506.
136. Lavi LE, Holcenberg JS (1985). A rapid and sensitive high-performance liquid chromatographic assay for 6-mercaptopurine metabolites in red blood cells. Anal Biochem 144: 514-521.
137. Lee SH, Sartorelli AC (1981). The effects of inhibitors of DNA biosynthesis on the cytotoxicity of 6-thioguanine. Cancer Biochem Biophys 5: 189-194.
138. Lemmer B, Bruguerolle B (1994). Chronopharmacokinetics. Are they clinically relevant? Clin Pharmacokinet 26: 419-427.
139. Lennard L, Rees CA, Lilleyman JS, et al. (1983). Childhood leukemia: A relationship between intracellular 6-mercaptopurine metabolism and neutropenia. Br J Clin Pharmacol 16: 359-363.
140. Lennard L, Keen D, Lilleyman JS (1986). Oral 6-mercaptopurine in childhood leukemia: Parent drug pharmacokinetics and active metabolite concentrations. Clin Pharmacol Ther 40: 287-292.
141. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM (1987). Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 41: 18-25.
142. Lennard L, Van Loon JA, Weinshilboum RM (1989). Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 46: 149-154.
143. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM (1990). Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336: 225-229.
144. Lennard L (1992). The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 43: 329-339.
145. Lennard L, Gibson BE, Nicole T, Lilleyman JS (1993a). Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 69: 577-579.
146. Lennard L, Hale JP, Lilleyman JS (1993b). Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukemia. Br J Clin Pharmacol 36: 277-284.
147. Lennard L, Welch J, Lilleyman JS (1995). Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance? Br J Cancer 72: 1004-1006.
148. Lennard L, Lilleyman JS (1987). Are children with lymphoblastic leukemia given enough 6-mercaptopurine? Lancet 2: 785-787.
149. Lennard L, Lilleyman JS (1989). Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia [published erratum appears in J Clin Oncol 1990 Mar; 8(3): 567]. J Clin Oncol 7: 1816-1823.
150. Lennard L, Maddocks JL (1983). Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine, and 6-thioguanine, in human red blood cells. J Pharm Pharmacol 35: 15-18.
151. Levin L, Simon R, Hryniuk W (1993). Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. J Natl Cancer Inst 85: 1732-1742.
152. Lewis AS, Murphy L, McCalla C, Fleary M, Purcell S (1984). Inhibition of mammalian xanthine oxidase by folate compounds and amethopterin. J Biol Chem 259: 12-15.
153. Liliemark J, Peterson C (1991). Pharmacokinetic optimisation of anticancer therapy. Clin Pharmacokinet 21: 213-231.
154. Lilleyman JS, Lennard L (1994). Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia. Lancet 343: 1188-1190.
155. Ling YH, Chan JY, Beattie KL, Nelson JA (1992a). Consequences of 6-thioguanine incorporation into DNA on polymerase, ligase, and endonuclease reactions. Mol Pharmacol 42: 802-807.
156. Ling YH, Nelson JA, Farquhar D, Beattie KL (1992b). Utilization of 2′-deoxy-6-thioguanosine 5′-triphosphate in DNA synthesis catalysed by DNA polymerase I Klenow fragment of Escherichia coli. Nucleosides Nucleotides 11: 23-35.
157. Lipshultz SE, Colan SD, Gelber RD, Perez Atayde AR, Sallan SE, Sanders SP (1991). Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324: 808-815.
158. Lonsdale D, Gehan EA, Fernbach DJ, Sullivan MP, Lane DM, Ragab AH (1975). Interrupted vs. continued maintenance therapy in childhood acute leukemia. Cancer 36: 341-352.
159. Look AT, Roberson PK, Murphy SB (1987). Prognostic value of cellular DNA content in acute lymphoblastic leukemia of childhood. N Eng J Med 315: 1666.
160. Lönnerholm G, Kreuger A, Lindström B, Ludvigsson J, Myrdal U (1986). Plasma and erythrocyte concentrations of mercaptopurine after oral administraion in children. Pediatr Hematol Oncol 33: 27-35.
161. Lönnerholm G, Kreuger A, Lindstrom B, Myrdal U (1989). Oral mercaptopurine in childhood leukemia: influence of food intake on bioavailability. Pediatr Hematol Oncol 6: 105-112.
162. Lucas K, Gula MJ, Blatt J (1992). Relapse in acute lymphoblastic leukemia as a function of white blood cell and absolute neutrophil counts during maintenance chemotherapy. Pediatr Hematol Oncol 9: 91-97.
163. Macdougall LG, McElligott SE, Ross E, Greeff MC, Poole JE (1992). Pattern of 6-mercaptopurine urinary excretion in children with acute lymphoblastic leukemia: urinary assays as a measure of drug compliance. Ther Drug Monit 14: 371-375.
164. Magrath IT, Steinberg SM, Adde MA, et al. (1989), Dose rate: An important prognostic determination in non-Hodgkin's lymphoma in young patients. Blood 74(suppl): 25a.
165. Mahony MJ, Murphy MS, Wadsworth J, Mott MG (1984). Modification of oral methotrexate absorption in children with leukemia. Cancer Chemother Pharmacol 12: 131-133.
166. Masson E, Relling MV, Synold TW, et al. (1996). Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 97: 73-80.
167. Mauer AM (1965), Diurnal variation of proliferative activity in the human bone marrow. Blood 26: 1-7.
168. McIntosh S, Davidson DL, O'Brien RT, Pearson HA (1977). Methotrexate hepatotoxicity in children with leukemia. J Pediatr 90: 1019-1021.
169. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE (1994). Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 55: 15-20.
170. Menard DB, Gisselbrecht C, Marty M, Reyes F, Dhumeaux D (1980). Antineoplastic agents and the liver. Gastroenterology 78: 142-164.
171. Meyer RM, Hryniuk WM, Goodyear MD (1991). The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 9: 339-347.
172. Miller DR, Coccia PF, Bleyer WA, et al. (1989). Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. J Clin Oncol 7: 1807-1815.
173. Milsap RL, Hill MR, Szefler SJ (1992). Special pharmacokinetic considerations in children. In: Evans WE, Schentag JJ, Jusko WJ, Relling MV (eds) Applied pharmacokinetics: Principles of therapeutic drug monitoring. 3rd edn. Applied Therapeutics, Inc, Vancouver: 10.1-10.32.
174. Mini E, Pizzorno G, Coronnello M, McGuire JJ, Mazzei T, Periti P, Bertino JR (1988). Impaired methotrexate polyglutamation in a human leukemia cell line resistant to short-term, high-dose methotrexate. Pharmacol Res Comm 20: 445-446.
175. Möttönen M (1993). A prospective survey of infections in children with acute lymphoblastic leukemia. The University of Oulu, Printing Center (Thesis).
176. Nelson JA, Carpenter JW, Rose LM, Adamson DJ (1975). Mechanisms of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine. Cancer Res 35: 2872-2878.
177. Nesbit M, Krivit W, Heyn R, Sharp H (1976). Acute and chronic effects of methotrexate on hepatic, pulmonary, and skeletal systems. Cancer 37: 1048-1057.
178. Newell DR, Pearseon ADJ, Balmanno K, et al. (1993). Carboplatin pharmacokinetics in children: The development of a pediatric dosing formula. J Clin Oncol 11: 2314-2323.
179. Nicholson JF, Pesce MA (1992). Laboratory medicine and reference tables. In: Behrman RE, Kliegman RM, Nelson WE, Vaughan III VC (eds) Nelson - Textbook of Pediatrics. 14th edn. W.B.Saunders Company, Philadelphia: 1797-1849.
180. Niemeyer CM, Reiter A, Riehm H, Donnelly M, Gelber RD, Sallan SE (1991). Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Munster and Dana-Farber Cancer Institute protocols. Ann Oncol 2: 745-749.
181. Olsen JH, Garwicz S, Hertz H, et al. (1993). Second malignant neoplasms after cancer in childhood or adolescence. Nordic Society of Paediatric Haematology and Oncology and Association of the Nordic Cancer Registries. BMJ 307: 1030-1036.
182. Osgood EE, Baker RL, Brownlee IE, Osgood MW, Ellis DM, Cohen W (1939). Total, differential and absolute leukocyte counts and sedimentation rates for healthy children. Am J Dis Child 58: 282-294.
183. Parker D, Bate CM, Craft AW, Graham Pole J, Malpas JS, Stansfeld AG (1980). Liver damage in children with acute leukaemia and non-Hodgkin's lymphoma on oral maintenance chemotherapy. Cancer Chemother Pharmacol 4: 121-127.
184. Parks RE, Jr., Brown PR, Cheng YC, Agarwal KC, Kong CM, Agarwal RP, Parks CC (1973). Purine metabolism in primitive erythrocytes. Comp Biochem Physiol B 45: 355-364.
185. Pearson AD, Craft AW, Eastham EJ, Aherne GW, Littleton P, Pearson GL, Campbell AN (1985). Small intestinal transit time affects methotrexate absorption in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 14: 211-215.
186. Pearson AD, Amineddine HA, Yule M, Mills S, Long DR, Craft AW, Chessells JM (1991). The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia. Br J Cancer 64: 169-173.
187. Peelers M, Koren G, Jakubovicz D, Zipursky-A (1988). Physician compliance and relapse rates of acute lymphoblastic leukemia in children. Clin Pharmacol Ther 43: 228-232.
188. Peters GJ, Schornagel JH, Milano GA (1993). Clinical pharmacokinetics of anti-metabolites. Cancer Surv 17: 123-156.
189. Peto R, Pike MC, Armitage P, et al. (1977). Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 35: 1-39.
190. Petros WP, Rodman JH, Mirro JJ, Evans WE (1991). Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia. Cancer Chemother Pharmacol 27: 397-400.
191. Pieters R, Huismans DR, Loonen AH, Hahlen K, van der Does van den Berg A, van Wering ER, Veerman AJ (1991). Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 338: 399-403.
192. Pinkel D, Hernandez K, Borella L, Holton C, Aur RJA, Samoy G, Pratt CB (1971). Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer 27: 247-256.
193. Pinkerton CR, Welshman SG, Glasgow JF, Bridges JM (1980). Can food influence the absorption of methotrexate in children with acute lymphoblastic leukemia. Lancet 2: 944-946.
194. Pinkerton CR, Glasgow JF, Bridges JM, Welshman SG (1981). Enterotoxic effect of methotrexate: does it influence the drug's absorption in children with acute lymphoblastic leukaemia? Br Med J Clin Res Ed 282: 1276-1277.
195. Pinkerton CR, Welshman SG, Kelly JG, Shanks RG, Bridges JM (1982). Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 10: 36-39.
196. Poplack DG, Balis FM, Zimm S (1986). The pharmacology of orally administered chemotherapy. A reappraisal. Cancer 58 (suppl): 473-480.
197. Poplack DG (1988). Acute lymphoblastic leukemia in childhood. In: Poplack D (ed) The Leukemias. WB Saunders, Philadelphia: 903-932.
198. Prasad R, Bacci G, Campanacci M, et al. (1990). Does drug dose intensity of chemotherapy determine the prognosis of primary high-grade osteosarcoma? Proc Am Soc Clin Oncol 9:311 (Abstract).
199. Pui CH, Ribeiro RC, Hancock ML, et al. (1991). Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325: 1682-1687.
200. Pui CH (1995). Childhood leukemias. N Eng J Med 332: 1618-1630.
201. Ramot B, Brok Simoni F, Chweidan E, Ashkenazi YE (1976). Blood leucocyte enzymes. III. Diurnal rhythm of activity in isolated lymphocytes of normal subjects and chronic lymphatic leukaemia patients. Br J Haematol 34: 79-85.
202. Ratain MJ (1992). Therapeutic relevance of pharmacokinetics and pharmacodynamics. Semin Oncol 4 (Suppl 11): S8-13.
203. Reiter A, Schrappe M, Ludwig WD, et al. (1994). Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84: 3122-3133.
204. Relling MV, Lin JS, Ayers GD, Evans WE (1992). Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 52: 643-658.
205. Riccardi R, Balis FM, Ferrasa P, Poplack DG, Mastrangelo R (1986). Influence of food intake on bioavailability of oral 6-mercaptopurine i children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 3: 319-324.
206. Riehm H, Gadner H, Henze G, et al. (1990). Results and significance of six randomized trials in four consecutive ALL-BFM studies. Hamatol Bluttransfus 33: 439-450.
207. Rivard GE, Infante-Rivard C, Hoyoux C (1985). Maintenance chemotherapy for childhood acute lymphoblastic leukemia: better in the evening. Lancet 2: 1264-1266.
208. Rivard GE, Infante Rivard C, Dresse MF, Leclerc JM, Champagne J (1993). Circadian time-dependent response of childhood lymphoblastic leukemia to chemotherapy: a long-term follow-up study of survival. Chronobiol Int 10: 201-204.
209. Rivera GK, Pinkel D, Simone JV, Hancock ML, Crist WM (1993). Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med 329: 1289-1295.
210. Robinson BA, Begg EJ, Colls BM, Jeffery CM, Sharman JR (1989). Circadian pharmacokinetics of methotrexate. Cancer Chemother Pharmacol 24: 397-399.
211. Rodman JH, Relling MV, Stewart CF, et al. (1993). Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children. Semin Oncol 20: 18-29.
212. Rosenberg IH (1976). Absorption and malabsorption of folates. Clin Haematol 5: 589-618.
213. Rosman M, Lee MH, Creasey WA, Sartorelli AC (1974). Mechanisms of resistance to 6-thiopurines in human leukemia. Cancer Res 34: 1952-1956.
214. Rosman M, Williams HE (1973). Leukocyte purine phosphoribosyl-transferases in human leukemias sensitive and resistant to 6-thiopurines. Cancer Res 33: 1202-1209.
215. Sarcione EJ, Stutzman L (1959). 6-methylmercaptopurine: identifica tion as metabolite of 6-mercaptopurine in vivo and in vitro. Proc Soc Exp Biol Med 101: 766-769.
216. Sather H, Coccia P, Nesbit M, Level C, Hammond D (1981). Disappearance of the predictive value of prognostic variables in childhood acute lymphoblastic leukemia; a report from Childrens Cancer Study Group. Cancer 48: 370-376.
217. Schabel FM, Jr., Griswold DP, Jr., Corbett TH, Laster WR, Jr. (1983). Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Pharmacol Ther 20: 283-305.
218. Schalhorn A, Sauer H, Wilmanns W, Stupp Poutot G (1982). Pharmacokinetics of erythrocyte methotrexate after high-dose methotrexate. Cancer Chemother Pharmacol 9: 65-69.
219. Schalhorn A (1983). Letter. Cancer Chemother Pharmacol 10: 231.
220. Schmiegelow K, Pulczynska MK, Seip M (1988). White-cell count during maintenance chemotherapy for standard-risk childhood acute lymphoblastic leukemia: relation to relapse rate. J Pediatr Hematol Oncol 5: 259-267.
221. Schmiegelow K, Schrøder H, Pulczynska MK, Hejl M (1989). Maintenance chemotherapy for childhood acute lymphoblastic leukemia: relation of bone-marrow and hepatotoxicity to the concentration of methotrexate in erythrocytes. Cancer Chemother Pharmacol 25: 65-69.
222. Schmiegelow K (1991). Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia [published erratum appears in Pediatr Hematol Oncol 1992 Apr-Jun;9(2): following 198]. Pediatr Hematol Oncol 8: 301-312.
223. Schmiegelow K, Schrøder H, Schmiegelow M (1994). Methotrexate and 6-mercaptopurine maintenance chemotherapy for childhood acute lymphoblastic leukemia: Dose adjustments by white cell counts or by pharmacokinetic parameters. Cancer Chemother Pharmacol 34: 209-215.
224. Schmiegelow K, Schrøder H, Gustafsson G, Kristinsson J, Glomstein A, Salmi T, Wranne L (1995). Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol 13: 345-351.
225. Schmiegelow K, Glomstein A, Kristinsson J, Salmi T, Schrøder H, Björk O (1997). Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. J Ped Hematol Oncol 1997; 19: 102-109.
226. Schmiegelow K, Bruunshuus I (1990). 6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia. Cancer Chemother Pharmacol 26: 288-292.
227. Schmiegelow K, Ifversen M (1996). Myelo- and hepatotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 13: 433-441.
228. Schmiegelow K, Pulczynska M (1990). Prognostic significance of hepatotoxicity during maintenance chemotherapy for childhood acute lymphoblastic leukaemia. Br J Cancer 61: 767-772.
229. Schmiegelow K, Pulczynska MK (1990a). Maintenance chemotherapy for childhood acute lymphoblastic leukemia: should dosage be guided by white blood cell counts? Am J Pediatr Hematol Oncol 12: 462-467.
230. Schmiegelow K, Pulczynska MK (1990b). White-cell counts in childhood acute lymphoblastic leukemia. Eur J Haematol 44: 72-74.
231. Scholar EM, Calabresi P (1973). Identification of the enzymatic pathways of nucleotide metabolism in human lymphocytes and leukemic cells. Cancer Res 33: 94-103.
232. Schnøder H (1986). Methotrexate pharmacokinetics in age-fractionated erythrocytes. Cancer Chemother Pharmacol 18: 203-207.
233. Schrøder H, Clausen N, Østergaard E, Pressler T (1986a). Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment. Cancer Chemother Pharmacol 16: 190-193.
234. Schrøder H, Clausen N, Østergard E, Pressler T (1986b). Folic acid supplements in vitamin tablets: a determinant of hematological drug tolerance in maintenance therapy of childhood acute lymphoblastic leukemia, Pediatr Hematol Oncol 3: 241-247.
235. Schrøder H, Fogh K, Herlin T (1988). In vivo decline of methotrexate and methotrexate poly glutamates in age-fractionated erythrocytes. Cancer Chemother Pharmacol 21: 150-155.
236. Schrøder H (1990). In vivo methotrexate kinetics and metabolism in human hematopoietic cells. Clinical significance of methotrexate concentrations in erythrocytes. Dan Med Bull 37: 22-40.
237. Schrøder H, Foged EK (1986). Methotrexate in erythrocytes of patients with psoriasis. Eur J Clin Pharmacol 30: 453-456.
238. Schrøder H, Fogh K (1988). Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia, Cancer Chemother Pharmacol 21: 145-149.
239. Shainoff JR (1968). A cellulose mercurial: preparation, properties and use in antibody formation. J Immunol 100: 187-193.
240. Sharper AG, Lewis P (1971). Genetic neutropenia in people of African origin. Lancet ii: 1021-1023.
241. Shorey J, Schenker S, Suki WN, Combes B (1968). Hepatotoxicity of mercaptopurine. Arch Intern Med 122: 54-58.
242. Siegel S, Castellan NJ (1988). Non-parametric statistics for the behavioral sciences. McGraw-Hill, Singapore.
243. Simon R, Wittes RE (1985). Methodological guidelines for reports on clinical trials. Cancer Treat Rep 69: 1-3.
244. Simone JV (1980). The treatment of acute lymphoblastic leukaemia. Br J Haematol 45: 1-4.
245. Sinclair D, Greaves L (1995) International register of current randomised protocols in childhood acute lymphoblastic leukemia. 2. eds (Catalog).
246. Skipper HE (1990). Dose intensity versus total dose of chemotherapy: an experimental basis. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology. J.B.Lippincott, Philadelphia: 43-64.
247. Sletvold O, Smaaland R, Laerum OD (1991). Cytometry and time-dependent variations in peripheral blood and bone marrow cells: a literature review and relevance to the chronotherapy of cancer. Chronobiol Int 8: 235-250.
248. Smaaland R, Lote K, Sothern RB, Laerum OD (1993). DNA synthesis and ploidy in non-Hodgkin's lymphomas demonstrate intrapatient variation depending on circadian stage of cell sampling. Cancer Res 53: 3129-3138.
249. Smith MA, Ungerleider RS, Horowitz M, E., Simon R (1991). Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. JNCI 83: 1460-1470.
250. Smith SD, Rosen D, Trueworthy RC, Lowman JT (1979). A reliable method for evaluating drug compliance in children with cancer. Cancer 43: 169-173.
251. Snodgrass W, Smith S, Trueworthy R, Vats T (1984). Pediatric clinical pharmacology of 6-mercaptopurine: Lack of compliance as a factor in leukemia relapse. Proc Am Soc Clin Oncol 3: 204 (Abstract).
252. Sonneveld P, Schultz FW, Nooter K, Hahlen K (1986). Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. Cancer Chemother Pharmacol 18: 111-116.
253. Steele WH, Stuart JF, Lawrence JR, McNeill CA (1982). The in vivo distribution of methotrexate between plasma and erythrocytes. Cancer Chemother Pharmacol 9: 110-113.
254. Steffensen J, Skulason T (1943). Das weisse Blutbild der Isländer. Soc Scient Islandica ii: 123-145.
255. Stuart JF, Calman KC, Watters J, et al. (1979). Bioavailability of methotrexate: implications for clinical use. Cancer Chemother Pharmacol 3: 239-241.
256. Sulh H, Koren G, Whalen C, et al. (1986). Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia. Clin Pharmacol Ther 40: 604-609.
257. Szumlanski C, Otterness D, Her C, et al. (1996). Thiopurine methyltranferase pharmacogenetics: Human gene cloning and characterization of a common polymorphism. DNA Cell Biol 15: 17-30.
258. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM (1992). Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 2: 148-159.
259. Tay BS, McLilley R, Murray AW, Atkinson MR (1969). Inhibition of phosphoribosyl pyrophosphate amidotransferase from Erlich ascites-tumor cells by thiopurine nucleotides. Biochem Pharmacol 18: 936-938.
260. Teresi ME, Crom WR, Choi KE, Mirro J, Evans WE (1987). Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr 110: 788-792.
261. The Medical Research Council's Working Party on Leukemia in Childhood (1985). Medical Research Council leukemia trial, UKALL VII. Arch Dis Child 60: 1050-1054.
262. The Medical Research Council's Working Party on Leukemia in Childhood (1986). Trial 1-8: Improvement in treatment for children with acute lymphoblastic leukemia. Lancet i: 408-411.
263. Tidd DM, Paterson AR (1974a). Distinction between inhibition of purine nucleotide synthesis and the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 34: 733-737.
264. Tidd DM, Paterson AR (1974b). A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 34: 738-746.
265. Topley JM, Benson J, Squier MV, Chessells JM (1979). Hepatotoxicity in the treatment of acute lymphoblastic leukaemia. Med Pediatr Oncol 7: 393-399.
266. Van Loon JA, Weinshilboum RM (1982). Thiopurine methyltransferase biochemical genetics: human lymphocyte activity. Biochem Genet 20: 637-658.
267. Van Loon JA, Weinshilboum RM (1987). Human lymphocyte thiopurine methyltransferase pharmacogenetics: effect of phenotype on 6-mercaptopurine-induced inhibition of mitogen stimulation. J Pharmacol Exp Ther 242: 21-26.
268. Van Scoik KG, Johnson CA, Porter WR (1985). The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine. Drug Metab Rev 16: 157-174.
269. Veerman AJP, Hählen K, Kamps WA, et al. (1996). High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: Results of protocol ALL VI. From the Dutch childhood leukemia study group. J Clin Oncol 14: 911-918.
270. Von Roemeling R (1991). The therapeutic index of cytotoxic chemotherapy depends upon circadian drug timing. Ann N Y Acad Sci 618: 292-311.
271. Warnick CT, Paterson ARP (1973). Effect of methyl thioinosine on nucleotide concentrations in L5178Y cells. Cancer Res 33: 1711-1715.
272. Warren DJ, Andersen A, Slordal L (1995). Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy. Cancer Res 55: 1670-1674.
273. Warren DJ, Slørdal L (1993). A high-performance liquid Chromatographic method for the determination of 6-thioguanine residues in DNA using precolumn derivatization and fluorescence detection. Anal Biochem 215: 278-283.
274. Weinshilboum RM, Raymond FH, Pazmino PA (1978). Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 85: 823-833.
275. Weinshilboum RM (1989). Thiol S-methyltransferases, II: Pharmacogenetics. In: Damani LA (ed) Sulphur-containing drugs and related organic compounds. Chemistry, biochemistry and toxicology. John Wiley & Sons, New York: 143-157.
276. Wheeler K, Leiper AD, Jannoun L, Chessells JM (1988). Medical cost of curing childhood acute lymphoblastic leukemia. Br Med J 296: 162-166.
277. White JC, Goldman ID (1976). Mechanism of action of methotrexate. Free intracellular methotrexate required to suppress dihydrofolate reduction to tetrahydrofolate by Erlich ascites tumor cells in vitro. Mol Pharmacol 12: 711-719.
278. Whitehead VM (1977). Synthesis of methotrexate polyglutamates in L1210 murine leukemia cells. Cancer Res 37: 408-412.
279. Whitehead VM, Rosenblatt DS, Vuchich MJ, et al. (1990). Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: A pilot prognostic factor analysis. Blood 213: 1-6.
280. Winick NJ, Kamen BA, Streckfuss A, et al. (1987). Methotrexate (MTX) concentration in tumors following low-dose MTX. Cancer Chemother Pharmacol 20: 78-80.
281. Wood AW, Seegmiller JE (1973). Properties of 5-phosphoribosyl-1-pyrophosphate amidotransferase from human lymphoblasts. J Biol Chem 248: 138-143.
282. Woodson LC, Dunnette JH, Weinshilboum RM (1982). Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. J Pharmacol Exp Ther 222: 174-181.
283. Woodson LC, Ames MM, Selassie CD, Mansch C, Weinshilboum RM (1983). Thiopurine methyltransferase. Aromatic thiol substrates and inhibition by benzoic acid derivatives. Mol Pharmacol 24: 471-478.
284. Workman P (1993). Pharmacokinetics and cancer: successes, failures and future prospects (editorial). Cancer Surv 17: 1-26.
285. Young MRI, Matthews JP, Kanabrocki EL, Sothern RB, Roitman-Johnson B, Scheving LE (1995). Circadian rhythmometry of serum interleukin-2, interleukin-10, tumor necrosis factor-alfa, and granulocyte-macrophage colony-stimulating factor in men. Chronobiol Int 1: 19-27.
286. Zachariae H, Kragballe K, Søgaard H (1985). Methotrexate induced liver cirrhosis. Br J Dermatol 102: 407-412.
287. Zachariae H, Schrøder H, Foged E, Søgaard H (1987). Methotrexate hepatotoxicity and concentrations of methotrexate and folate in erythrocytes-relation to liver fibrosis and cirrhosis. Acta Derm Venereol Stockh 67: 336-340.
288. Zimm S, Collins JM, O'Neill D, Chabner BA, Poplack DG (1983a). Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 34: 810-817.
289. Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner BA, Poplack DG (1983b). Variable bioavailability of oral mercaptopurine: is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Eng J Med 308: 1005-1009.
290. Zimm S, Reaman G, Murphy RF, et al. (1986). Biochemical parameters of mercaptopurine activity in patients with acute lymphoblastic leukemia. Cancer Res 46: 1495-1498.
291. Zimmerman TP, Chu LC, Bugge CJ, Nelson DJ, Lyon GM, Elion GB (1974). Identification of 6-methylmercaptopurine ribonucleoside 5′-diphosphate and 5′-triphosphate as metabolites of 6-mercaptopurine in man. Cancer Res 34: 221-224.